| NCT ID | NCT04978948 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Brest |
| Condition | Autoimmune Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 670 participants |
| Start Date | 2021-05-11 |
| Primary Completion | 2027-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 670 participants in total. It began in 2021-05-11 with a primary completion date of 2027-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to determine the expression of STIM1 in the plasma membrane of lymphocytes from patients suffering from different autoimmune diseases in order to identify new pathologies of interest presenting an over-expression of STIM1PM. This would allow to initiate, following this study, research and development programs on the use of anti-STIM1 antibodies in these identified autoimmune diseases of interest.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of one of the autoimmune diseases Exclusion Criteria: * Treatment with rituximab in the previous 12 months
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04978948 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Autoimmune Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04978948 currently recruiting?
Yes, NCT04978948 is actively recruiting participants. Contact the research team at divi.cornec@chu-brest.fr for enrollment information.
Where is the NCT04978948 trial being conducted?
This trial is being conducted at Brest, France, Morlaix, France, Quimper, France, Fort-de-France, France.
Who is sponsoring the NCT04978948 clinical trial?
NCT04978948 is sponsored by University Hospital, Brest. The trial plans to enroll 670 participants.